Lee Ratner1. 1. Division of Molecular Oncology, Washington University, 660 South Euclid Avenue, Saint Louis, MO 63110, USA. lratner@im.wustl.edu
Abstract
PURPOSE OF REVIEW: This article summarizes the current pathophysiologic basis for human T cell lymphotropic virus-associated leukemia/lymphoma as well as past, present, and future therapeutic options. RECENT FINDINGS: New studies have been published on allogeneic stem cell transplantation, arsenic trioxide, and bortezomib for this condition. SUMMARY: Studies of the molecular biology of human T cell lymphotropic virus-1-induced T cell leukemia/lymphoma have defined a critical role for oncoprotein, Tax, and activation of nuclear factor kappaB transcription pathways, which have provided rational approaches to improved therapy for T cell leukemia/lymphoma as well as a model for other hematopoietic malignancies characterized by nuclear factor kappaB activation.
PURPOSE OF REVIEW: This article summarizes the current pathophysiologic basis for human T cell lymphotropic virus-associated leukemia/lymphoma as well as past, present, and future therapeutic options. RECENT FINDINGS: New studies have been published on allogeneic stem cell transplantation, arsenic trioxide, and bortezomib for this condition. SUMMARY: Studies of the molecular biology of human T cell lymphotropic virus-1-induced T cell leukemia/lymphoma have defined a critical role for oncoprotein, Tax, and activation of nuclear factor kappaB transcription pathways, which have provided rational approaches to improved therapy for T cell leukemia/lymphoma as well as a model for other hematopoietic malignancies characterized by nuclear factor kappaB activation.
Authors: A Bazarbachi; M E El-Sabban; R Nasr; F Quignon; C Awaraji; J Kersual; L Dianoux; Y Zermati; J H Haidar; O Hermine; H de Thé Journal: Blood Date: 1999-01-01 Impact factor: 22.113
Authors: O Hermine; D Bouscary; A Gessain; P Turlure; V Leblond; N Franck; A Buzyn-Veil; B Rio; E Macintyre; F Dreyfus Journal: N Engl J Med Date: 1995-06-29 Impact factor: 91.245
Authors: P S Gill; W Harrington; M H Kaplan; R C Ribeiro; J M Bennett; H A Liebman; M Bernstein-Singer; B M Espina; L Cabral; S Allen Journal: N Engl J Med Date: 1995-06-29 Impact factor: 91.245
Authors: H Taguchi; K I Kinoshita; K Takatsuki; M Tomonaga; K Araki; N Arima; S Ikeda; K Uozumi; H Kohno; F Kawano; H Kikuchi; H Takahashi; K Tamura; S Chiyoda; H Tsuda; H Nishimura; T Hosokawa; H Matsuzaki; S Momita; O Yamada; I Miyoshi Journal: J Acquir Immune Defic Syndr Hum Retrovirol Date: 1996-06-01
Authors: T A Waldmann; J D White; J A Carrasquillo; J C Reynolds; C H Paik; O A Gansow; M W Brechbiel; E S Jaffe; T A Fleisher; C K Goldman; L E Top; R Bamford; E Zaknoen; E Roessler; C Kasten-Sportes; R England; H Litou; J A Johnson; T Jackson-White; A Manns; B Hanchard; R P Junghans; D L Nelson Journal: Blood Date: 1995-12-01 Impact factor: 22.113
Authors: P Martín-Dávila; J Fortún; R López-Vélez; F Norman; M Montes de Oca; P Zamarrón; M I González; A Moreno; T Pumarola; G Garrido; A Candela; S Moreno Journal: Clin Microbiol Rev Date: 2008-01 Impact factor: 26.132
Authors: Anwaar Ahmad; Jason S Groshong; Hittu Matta; Sandra Schamus; Vasu Punj; Lisa J Robinson; Parkash S Gill; Preet M Chaudhary Journal: Cancer Biol Ther Date: 2010-11-15 Impact factor: 4.742
Authors: Lisa G Lanigan; Blake E Hildreth; Wessel P Dirksen; Jessica K Simmons; Chelsea K Martin; Jillian L Werbeck; Nandu K Thudi; Tracey L Papenfuss; Prosper N Boyaka; Ramiro E Toribio; Jerrold M Ward; Katherine N Weilbaecher; Thomas J Rosol Journal: Am J Pathol Date: 2020-11-09 Impact factor: 4.307